Yes, you can and should initiate both SGLT2 inhibitor and ACE inhibitor (or ARB) in this patient with UPCR 1.7 and eGFR 27.
With an eGFR of 27 mL/min/1.73 m² and significant proteinuria (UPCR 1.7 g/g, equivalent to approximately 1700 mg/g), this patient meets clear guideline criteria for both SGLT2 inhibitor and RAS inhibitor therapy, and these agents should be used together for maximal kidney and cardiovascular protection 1.
SGLT2 Inhibitor Initiation
Start the SGLT2 inhibitor immediately. The 2024 KDIGO guidelines provide a strong 1A recommendation for SGLT2 inhibitor use in adults with CKD and eGFR ≥20 mL/min/1.73 m² when UACR ≥200 mg/g (equivalent to UPCR ≥0.2 g/g) 1. Your patient's UPCR of 1.7 far exceeds this threshold, making SGLT2 inhibitor therapy strongly indicated.
Key implementation points:
- The eGFR of 27 is well above the initiation threshold of 20 mL/min/1.73 m²
- Once started, continue the SGLT2 inhibitor even if eGFR subsequently falls below 20, unless intolerance or dialysis initiation occurs 1
- Expect and accept an initial reversible eGFR decline of 3-5 mL/min/1.73 m² - this does not require discontinuation and reflects beneficial hemodynamic changes 1, 2
- Temporarily withhold during prolonged fasting, surgery, or critical illness due to ketosis risk 1
RAS Inhibitor (ACE or ARB) Initiation
Also initiate ACE inhibitor or ARB therapy. The 2024 KDIGO guidelines explicitly state to continue RAS inhibitors even when eGFR falls below 30 mL/min/1.73 m² 1. With significant proteinuria (UPCR 1.7), RAS blockade remains a cornerstone therapy.
Key implementation points:
- Use the highest approved tolerated dose, as trial benefits were achieved at these doses 1
- Check BP, creatinine, and potassium within 2-4 weeks of initiation 1
- Continue therapy unless creatinine rises >30% within 4 weeks of starting 1
- Manage hyperkalemia with potassium-lowering measures rather than stopping the RAS inhibitor 1
- Only reduce dose or discontinue for symptomatic hypotension, uncontrolled hyperkalemia despite treatment, or uremic symptoms at eGFR <15 1
Combination Therapy Evidence
The combination of SGLT2 inhibitor plus RAS inhibitor is not only safe but provides additive benefits. Research demonstrates that adding SGLT2 inhibitors to RAS blockade produces:
- Additional albuminuria reduction beyond RAS inhibition alone 3, 2
- Additive blood pressure lowering (systolic BP reduced by additional 4 mmHg, diastolic by 3 mmHg) 2
- Reduced oxidative stress markers 2
- Suppression of inflammatory and fibrotic pathways 4
The expected initial eGFR dip with SGLT2 inhibitor addition (approximately 8 mL/min/1.73 m² when added to ACE inhibitor) reflects beneficial reduction in intraglomerular pressure and is protective, not harmful 2.
Regarding ARNI (Angiotensin Receptor-Neprilysin Inhibitor)
For CKD without heart failure with reduced ejection fraction, stick with ACE inhibitor or ARB rather than ARNI. The guidelines specifically recommend RAS inhibitors (ACE inhibitors or ARBs) for CKD with proteinuria 1. ARNI is primarily indicated for heart failure with reduced ejection fraction. Unless your patient has concurrent HFrEF, use standard ACE inhibitor or ARB.
Monitoring Plan
After initiating both agents:
- Recheck creatinine, potassium, and BP in 2-4 weeks 1
- Accept initial eGFR decline up to 30% as physiologic and beneficial 1
- Continue standard CKD monitoring frequency - SGLT2 inhibitor initiation does not require more frequent monitoring 1
- Monitor for volume depletion symptoms, especially if on diuretics
Common Pitfall to Avoid
Do not withhold SGLT2 inhibitor due to the eGFR of 27. Many clinicians mistakenly believe SGLT2 inhibitors should only be started at higher eGFR levels. The evidence and guidelines are clear: initiation is appropriate and beneficial down to eGFR 20 mL/min/1.73 m² when proteinuria is present 5, 1.